CYT — Cyteir Therapeutics Share News
0.000.00%
Last trade - 00:00- $111.95m
- -$17.29m
Brief: Cyteir Therapeutics Timothy Romberger Resigned From Board & All Of Its Committees
Brief: Ongoing Results From A Dose Expansion Cohort Of Cyt-0851 In Combination With Capecitabine In Advanced Platinum-Resistant Ovarian Cancer Show Promising Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Announces Discontinuation Of Cyt-0851 Development Program And Planned Liquidation And Dissolution
Brief: Cyteir Says Preliminary Ongoing Results With CYT-0851 In Combination With Capecitabine Or Gemcitabine In Advanced Solid Tumors Show Early Clinical Activity And Generally Well Tolerated Safety Profile
Brief: Cyteir Therapeutics Reports First Quarter 2023 Financial Results And Operational Highlights
Brief: Cyteir Therapeutics Reports Fourth Quarter Results
Brief: Cyteir Therapeutics Promotes David Gaiero To Chief Financial Officer
U.S. STOCKS ON THE MOVE-Eli Lilly, Tesla, Kohl's, Ally Financial
U.S. STOCKS ON THE MOVE-Netflix, PagerDuty, Proterra
U.S. STOCKS ON THE MOVE-Biogen, Wayfair, Costco
Cyteir Therapeutics cuts workforce by 70%, JPM downgrades rating
U.S. RESEARCH ROUNDUP-Concert Pharmaceuticals, Cyteir Therapeutics, LCI Industries
Brief: Cyteir Therapeutics Announces Prioritization Of CYT-0851 Development
Brief: Cyteir Therapeutics Inc Reports Q3 Loss Per Share Of $0.31
Brief: Cyteir Therapeutics Reports Second Quarter 2022 Financial Results And Operational Highlights
Brief: Cyteir Therapeutics Inc Files For Mixed Shelf Of Up To $300 Million - SEC Filing
Brief: Cyteir Therapeutics Says CYT-0851 Phase 1 Results Show Well Tolerated Safety Profile In Advanced Solid Tumors
U.S. RESEARCH ROUNDUP- Black Knight, Dish Network, Whirlpool
Brief: Cyteir Therapeutics Reports First Quarter 2022 Financial Results